To the Editor: The radiation oncology community in South Africa can no longer support the continuation of neutron therapy
in malignant salivary gland tumors: Results at European centers.
He suggests a change in the way patients are chosen for neutron therapy
The majority of the increase occurred in May 2011 upon the acquisition of an interest in a cancer neutron therapy company.
Additionally, the neutron therapy company has a claim against $5 million in warrant proceeds when and if those are paid in.
Firstly, the rhetoric supporting the purported importance of recent research on neutron therapy, and the charge that Prof Abratt's view of neutron therapy is outdated, are simply unreasonable.
Despite the claims of the proponents of such research on the topic of neutron therapy, we note a paucity of well-structured published research on the role of this treatment modality.
Located near Princeton, NJ, Hadron is focused on developing the techniques and devices to support slow neutron therapy
for cancers, including the targeting and ablation of tumor stroma cells, without which tumors cannot form.
Prof Abratt's opinion was held in the late 1980s when severe late effects of fast neutron therapy (FNT) were recognised, resulting in the early enthusiasm for this modality abating.
However, for some indications, neutron therapy remains superior to other modalities, despite advances in oncology.
To the Editor: Neutron therapy
for tumours was introduced globally and in South Africa to evaluate the possible improvement of results obtained with conventional photon radiotherapy.
Fast Neutron Therapy
is very powerful and radiobiologically very advantageous to the patient.